Hepatic injury caused by benzbromarone.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Hepatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8278(94)80011-1PMID 8014449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics and biotransformation of benzbromarone in man

  2004cited by this paper
• Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles

  2004cited by this paper
• Liquid chromatography-mass spectrometry in metabolic research. I. Metabolites of benzbromarone in human plasma and urine.

  1991cited by this paper
• Perfusion chromatography packing materials for proteins and peptides

  1991cited by this paper
• Hépatite à la benzarone: un deuxième cas.

  1990cited by this paper
• [Hepatitis caused by benzarone: a second case].

  1990cited by this paper
• [Drug-induced hepatitis due to benzarone (Fragivix): apropos of a clinical case report].

  1990cited by this paper
• Urinary metabolites of benzbromarone in man.

  1990cited by this paper
• Hépatite médicamenteuse liée à la benzarone (Fragivix): à propos d'une observation clinique.

  1990cited by this paper
• Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone

  1988cited by this paper
• Chronic active hepatitis caused by benzarone.

  1987cited by this paper
• Metabolic fate of the thrombolytic agent benzarone in man: comparison with the rat and dog.

  1987cited by this paper
• Analysis of benzbromarone in human plasma and urine by high-performance liquid chromatography and gas chromatography-mass spectrometry.

  1987cited by this paper
• Ten years' experience with benzbromarone in the management of gout and hyperuricaemia.

  1981cited by this paper
• Metabolism of benzbromarone in man

  1972cited by this paper
• Jaundice and Cardivix

  1964cited by this paper

• Benzbromarone improves blood hypercoagulability after TBI by reducing phosphatidylserine externalization through inhibition of TMEM16F expression.

  2025cites this paper
• Reply

  2025cites this paper
• Benzoheterocyclic analogues of dotinurad as orally efficacious human urate transporter 1 inhibitors: Design, synthesis, structure-activity relationships, and pharmacokinetic studies.

  2025cites this paper
• Risk of hepatotoxicity in use of febuxostat or benzbromarone: comment on the article by Sun et al

  2025cites this paper
• Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double‐Blind, Phase 3 Trial in China

  2025cites this paper
• Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor

  2024cites this paper
• 3,5-dicaffeoylquinic Acid Promotes Intestinal Urate Excretion via the MAPK Signaling Pathway Based on Caco-2 Cell Model

  2024cites this paper
• Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia.

  2023cites this paper
• Agents for the Treatment of Gout: Current Advances and Future Perspectives.

  2023cites this paper
• Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia

  2022cites this paper
• Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.

  2022cites this paper
• OARRR_A_282631 111..122

  2021cites this paper
• Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout

  2021cites this paper
• Contentious Issues in Gout Management: The Story so Far

  2021cites this paper
• Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database.

  2021cites this paper
• Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study

  2020cites this paper
• A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout

  2020cites this paper
• The uricosuric benzbromarone disturbs the mitochondrial redox homeostasis and activates the NRF2 signaling pathway in HepG2 cells.

  2020cites this paper
• URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.

  2019cites this paper
• Benzbromarone in the treatment of gout

  2019cites this paper
• Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment

  2019cites this paper
• Liver failure associated with benzbromarone: A case report and review of the literature

  2019cites this paper
• Application of UHPLC/ESI-Q-TOF-MS/MS to Identify Constituents of Erding Granule and Anti-hyperuricemia Effect

  2019cites this paper
• Benzbromarone aggravates hepatic steatosis in obese individuals.

  2018cites this paper
• Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation.

  2018cites this paper
• Management of complex gout in clinical practice: Update on therapeutic approaches.

  2018cites this paper
• Association of a reactive intermediate derived from 1′,6‐dihydroxy metabolite with benzbromarone‐induced hepatotoxicity

  2017cites this paper
• Identification of novel glutathione adducts of benzbromarone in human liver microsomes.

  2017cites this paper
• Strategic Drug Design to Avoid the Metabolic Activation of Hepatotoxic Drugs.

  2017cites this paper
• Comparative study on the interaction between 3 CYP2C9 allelic isoforms and benzbromarone by using LC-MS/MS method.

  2017cites this paper
• Autoimmune hepatitis following drug-induced liver injury in an elderly patient

  2016cites this paper
• Novel Bioactivation Pathway of Benzbromarone Mediated by Cytochrome P450

  2015cites this paper
• Novel Bioactivation Pathway of Benzbromarone Mediated by Cytochrome P450

  2015cites this paper
• TITLE Novel Bioactivation Pathway of Benzbromarone Mediated by Cytochrome P 450

  2015cites this paper
• Pharmacogenetic considerations in the treatment of gout.

  2015cites this paper
• Novel Bioactivation Pathway of Benzbromarone Mediated by Cytochrome P450

  2015cites this paper
• Novel Bioactivation Pathway of Benzbromarone Mediated by Cytochrome P450

  2015cites this paper
• Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure.

  2014cites this paper
• Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients

  2014cites this paper
• Management of nonvariceal upper gastrointestinal bleeding resistant to endoscopic haemostasis: Will transcatheter embolization replace surgery? Author reply.

  2013cites this paper
• Management of Hyperuricemia and Gout

  2013cites this paper
• Nonsteroidal antiinflammatory drugs and leukotriene receptor antagonists

  2013cites this paper
• Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today?

  2013cites this paper
• Cytotoxic effects of benzbromarone and its 1'-hydroxy metabolite in human hepatocarcinoma FLC4 cells cultured on micro-space cell culture plates.

  2013cites this paper
• Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome developed in a patient with vitiligo and Hashimoto thyroiditis.

  2013cites this paper
• Benzbromarone: a double-edged sword that cuts the liver?

  2013cites this paper
• Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes

  2012cites this paper
• Metabolism studies of benzbromarone in rats by high performance liquid chromatography-quadrupole time of flight mass spectrometry.

  2012cites this paper
• Gout in Solid Organ Transplantation

  2012cites this paper
• Interactions of urate transporter URAT1 in human kidney with uricosuric drugs

  2011cites this paper
• The Challenges of Gout Management in the Elderly

  2011cites this paper
• Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.

  2011cites this paper
• Mitochondrial involvement in drug-induced liver injury.

  2010cites this paper
• Drug-induced eosinophilic pneumonia with pulmonary alveolar hemorrhage caused by benzbromarone.

  2010cites this paper
• Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

  2009cites this paper
• allopurinolversus probenecid after failure of gout: a randomised controlled trial of Efficacy and tolerability of urate-lowering drugs in

  2009cites this paper
• Clinical Studies Including Therapeutics (ESCISIT) EULAR Standing Committee For International Part II: Management. Report of a task force of the EULAR evidence based recommendations for gout.

  2009cites this paper
• Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities.

  2008cites this paper
• Practice research in the field of gout - clinical pharmacology of antihyperuricemic drugs

  2008influential citation
• Effects of Benzbromarone and Allopurinol on Adiponectin In Vivo and In Vitro

  2008cites this paper
• Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol

  2008cites this paper
• A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout

  2008influential citation
• Activating Effect of Benzbromarone, a Uricosuric Drug, on Peroxisome Proliferator-Activated Receptors

  2007cites this paper
• Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients

  2007cites this paper
• Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate.

  2007cites this paper
• Clinical trials in crystal arthropathy.

  2006cites this paper
• EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)

  2006cites this paper
• Gout in solid organ transplantation: a challenging clinical problem.

  2005cites this paper
• Mechanisms of benzarone and benzbromarone-induced hepatic toxicity.

  2005cites this paper
• A Small Dose of Toxicology: Role of Mitochondrial Dysfunction in Hepatic and Skeletal Muscle Toxicity

  2005cites this paper
• Mechanisms of benzarone and benzbromarone‐induced hepatic toxicity

  2005cites this paper
• ベンズブロマロンによる肝障害が疑われたNASH(nonalcoholic steatohepatitis)の痛風症例

  2005cites this paper
• Benzbromarone (商品名: ユリノーム) による劇症肝炎亜急性型の1例

  2004cites this paper
• Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"?

  2004cites this paper
• A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives.

  2003cites this paper
• Modern Therapy of Crystal Arthropathies

  2002cites this paper
• Fulminant hepatic failure associated with benzbromarone treatment: A case report

  2002cites this paper
• Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria.

  2001cites this paper
• Letters to the Editor: Fatal fulminant hepatic failure associated with benzbromarone

  2000cites this paper
• Fatal fulminant hepatic failure associated with benzbromarone.

  2000cites this paper
• Management of crystal arthritis.

  1999cites this paper
• [Drug-induced hepatitis: diagnosis and treatment].

  1999cites this paper
• Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

  1998cites this paper
• Publications et pharmacovigilance : pourquoi et comment ?

  1997cites this paper
• [Publications and postmarketing product surveillance: why and how?].

  1997cites this paper
• Enhancement of Anticoagulant Action by Warfarin—Benzbromarone Interaction

  1996cites this paper
• Enhancement of Anticoagulant Effect of Warfarin by Benzbromarone, an Uricosuric Drug

  1995cites this paper
• Anti-inflammatory analgesics and drugs used in gout

  1994cites this paper